299 related articles for article (PubMed ID: 32248831)
21. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
Stepien KM; Hendriksz CJ; Roberts M; Sharma R
Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
[TBL] [Abstract][Full Text] [Related]
22. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of Pompe disease in China: a report from the Pompe registry.
Zhao Y; Wang Z; Lu J; Gu X; Huang Y; Qiu Z; Wei Y; Yan C
Orphanet J Rare Dis; 2019 Apr; 14(1):78. PubMed ID: 30943998
[TBL] [Abstract][Full Text] [Related]
24. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
[TBL] [Abstract][Full Text] [Related]
25. A Comprehensive Update on Late-Onset Pompe Disease.
Labella B; Cotti Piccinelli S; Risi B; Caria F; Damioli S; Bertella E; Poli L; Padovani A; Filosto M
Biomolecules; 2023 Aug; 13(9):. PubMed ID: 37759679
[TBL] [Abstract][Full Text] [Related]
26. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
[TBL] [Abstract][Full Text] [Related]
27. Early-onset of symptoms and clinical course of Pompe disease associated with the c.-32-13 T > G variant.
Herbert M; Case LE; Rairikar M; Cope H; Bailey L; Austin SL; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):106-116. PubMed ID: 30655185
[TBL] [Abstract][Full Text] [Related]
28. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B; Kishnani PS; Bratkovic D; Byrne BJ; Claeys KG; Díaz-Manera J; Laforêt P; Roberts M; Toscano A; van der Ploeg AT; Castelli J; Goldman M; Holdbrook F; Sitaraman Das S; Wasfi Y; Mozaffar T;
J Neurol; 2024 May; 271(5):2810-2823. PubMed ID: 38418563
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study.
Wenninger S; Greckl E; Babačić H; Stahl K; Schoser B
J Neurol; 2019 Jan; 266(1):133-147. PubMed ID: 30430231
[TBL] [Abstract][Full Text] [Related]
30. Identification of Seven Novel Mutations in the Acid Alpha-glucosidase Gene in Five Chinese Patients with Late-onset Pompe Disease.
Liu HX; Pu CQ; Shi Q; Zhang YT; Ban R
Chin Med J (Engl); 2018 Feb; 131(4):448-453. PubMed ID: 29451150
[TBL] [Abstract][Full Text] [Related]
31. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.
Angelini C; Semplicini C; Ravaglia S; Bembi B; Servidei S; Pegoraro E; Moggio M; Filosto M; Sette E; Crescimanno G; Tonin P; Parini R; Morandi L; Marrosu G; Greco G; Musumeci O; Di Iorio G; Siciliano G; Donati MA; Carubbi F; Ermani M; Mongini T; Toscano A;
J Neurol; 2012 May; 259(5):952-8. PubMed ID: 22081099
[TBL] [Abstract][Full Text] [Related]
32. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
Kuperus E; Kruijshaar ME; Wens SCA; de Vries JM; Favejee MM; van der Meijden JC; Rizopoulos D; Brusse E; van Doorn PA; van der Ploeg AT; van der Beek NAME
Neurology; 2017 Dec; 89(23):2365-2373. PubMed ID: 29117951
[TBL] [Abstract][Full Text] [Related]
33. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM
J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135
[TBL] [Abstract][Full Text] [Related]
34. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study.
Confalonieri M; Vitacca M; Scala R; Polverino M; Sabato E; Crescimanno G; Ceriana P; Antonaglia C; Siciliano G; Ring N; Zacchigna S; Salton F; Vianello A;
Orphanet J Rare Dis; 2019 Mar; 14(1):62. PubMed ID: 30832705
[TBL] [Abstract][Full Text] [Related]
35. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
Dimachkie MM; Barohn RJ; Byrne B; Goker-Alpan O; Kishnani PS; Ladha S; Laforêt P; Mengel KE; Peña LDM; Sacconi S; Straub V; Trivedi J; Van Damme P; van der Ploeg AT; Vissing J; Young P; Haack KA; Foster M; Gilbert JM; Miossec P; Vitse O; Zhou T; Schoser B;
Neurology; 2022 Aug; 99(5):e536-e548. PubMed ID: 35618441
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
[TBL] [Abstract][Full Text] [Related]
37. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis.
Berger KI; Kanters S; Jansen JP; Stewart A; Sparks S; Haack KA; Bolzani A; Siliman G; Hamed A
J Neurol; 2019 Sep; 266(9):2312-2321. PubMed ID: 31187190
[TBL] [Abstract][Full Text] [Related]
38. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T
J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608
[TBL] [Abstract][Full Text] [Related]
39. Effects of enzyme replacement therapy on bone density in late onset Pompe disease.
Avanti M; Martin A; Columbres RC; Mozaffar T; Kimonis V
Mol Genet Metab; 2023 Nov; 140(3):107644. PubMed ID: 37515933
[TBL] [Abstract][Full Text] [Related]
40. Investigation on acute effects of enzyme replacement therapy and influence of clinical severity on physiological variables related to exercise tolerance in patients with late onset Pompe disease.
Sechi A; Salvadego D; Da Ponte A; Bertin N; Dardis A; Cattarossi S; Devigili G; Reccardini F; Bembi B; Grassi B
Neuromuscul Disord; 2017 Jun; 27(6):542-549. PubMed ID: 28433478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
